Theravance Biopharma (TBPH) Receivables - Other (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Receivables - Other data on file, last reported at $15.6 million in Q1 2026.

• On a quarterly basis, Receivables - Other rose 1.5% year-over-year to $15.6 million in Q1 2026; TTM through Mar 2026 was $15.6 million, a 1.5% increase from a year earlier, with the FY2025 full-year figure at $45.5 million, up 146.96% from the prior year.
• Receivables - Other for Q1 2026 stood at $15.6 million, down from $45.5 million in the prior quarter.
• Over the last five years, Receivables - Other for TBPH reached as high as $45.5 million in Q4 2025 and fell as low as $12.3 million in Q1 2023.
• Historically, Receivables - Other has averaged $19.0 million across 5 years, with a median of $16.8 million in 2022.
• Across the five-year window, Receivables - Other sank 65.49% in 2023 and surged 146.96% in 2025, its largest moves.
• Year by year, Receivables - Other stood at $16.8 million in 2022, then grew by 4.1% to $17.5 million in 2023, then grew by 5.53% to $18.4 million in 2024, then soared by 146.96% to $45.5 million in 2025, then sank by 65.78% to $15.6 million in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $15.6 million in Q1 2026, $45.5 million in Q4 2025, and $18.3 million in Q3 2025.